Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RaSOLVE: An Open-Label, Controlled, Randomized, Multicenter Phase III Clinical Trial Assessing the Impact of Preoperative 125I Radioactive Seed Localization on Pathological Complete Response Rate (tpCR: ypT0/is ypN0) and Long-Term Prognosis (iDFS/OS) in Women With Early or Locally Advanced Newly Diagnosed Untreated Breast Cancer Following Neoadjuvant Therapy

NCT07269691 is registered in ClinicalTrials.gov with Pengfei Qiu as lead sponsor.

NCT NCT07269691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07269691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RaSOLVE: An Open-Label, Controlled, Randomized, Multicenter Phase III Clinical Trial Assessing the Impact of Preoperative 125I Radioactive Seed Localization on Pathological Complete Response Rate (tpCR: ypT0/is ypN0) and Long-Term Prognosis (iDFS/OS) in Women With Early or Locally Advanced Newly Diagnosed Untreated Breast Cancer Following Neoadjuvant Therapy
Lead sponsor
Pengfei Qiu
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
December 1, 2027
Enrollment
194 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer early stage breast cancer (stage 1-3)